COVID-19 inhibition assay is on MedRxiv!

Congrats to Ted on his first, first-author paper describing some new IP-FCM assays that he’s been working non-stop on for the past two months. We detect anti-SARS-CoV-2 antibodies in almost all recovered patients, and we detect inhibition of SARS-2 spike protein binding to its receptor, ACE2. Our cell-free inhibition assay, based on IP-FCM, could be useful to quantify immunity in recovered patients or vaccine trials. Big thanks to our collaborators at SCRI, Drs. Whitney Harrington, Noah Sather and Lisa Frenkel. We’re very proud to be a small part of the global, collaborative effort to fight COVID-19.

Lab technician wanted

An entry-level tab technician position is available in the SEPS lab at SCRI! The ideal candidate will have a strong interest in molecular biology, neuroscience and/or immunology, as well as some basic undergraduate experience in a lab environment. Prior experience with Luminex bead-based assays, proteomics and/or flow cytometry are desirable. More than any specific skill, we seek a candidate who is intelligent, driven, good with a pipette, and willing and able to learn new techniques. Duties include genotyping and maintenance of the mouse colony, daily running of the QMI assay (video available on JOVE), neuronal tissue culture, and general lab upkeep. The SEPS lab is a fast-paced, collaborative and friendly environment, so the ability to work well as a team is also critical. Please submit a cover letter and CV through the Seattle Children’s job site , and an email to introduce yourself won’t hurt either!

SEPS lab is awarded an R01 from NCI!

In collaboration with Mike Jensen’s CAR T cell group, the SEPS lab has been awarded a 5-year grant from the National Cancer Institute! Will will use our QMI platform to investigate how CAR T cells transmit intracellular activation signals upon antigen engagement. We hope identify protein interactions that correlate with positive or negative outcomes, in order to perform a ‘personalized signal transduction analysis’ for each batch of cells, before infusion into the patient. More to come…